ThinkstockAt a press conference on Thursday afternoon, President Obama announced that the number of Americans using the public exchanges to enroll in a health insurance plan rose to 8 million after the deadline passed…
UnitedHealth Group reported better-than-expected first-quarter earnings before markets opened Thursday, but revenues fell short of consensus estimates.
ThinkstockSome initial public offerings (IPOs) are considered a huge success if the stock appreciates more than about 20% on its IPO date. To some, though, that’s an unsuccessful launch from the company’s point of…
Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes the price target upside is off the charts as well. In case of Lpath…
Johnson & Johnson reported better-than-expected first-quarter results before markets opened Tuesday morning. And the company boosted its earnings guidance for the full year.
Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance also allowed sellers to keep exiting the sector.
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many of them. The largest…
The $5.6 billion acquisition of Questcor Pharmaceuticals by specialty drugmaker Mallinckrodt started the week off with a big bang. But just what did Mallinckrodt get?
While the FDA has been far from a friend to MannKind over the past few years, the latest FDA panel backing may have given diabetes patients and investors some hope. That hope was diminished…
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Halozyme Therapeutics shares are getting pounded on Friday on news of a temporary halt of its Phase II trial enrollment and dosing for its pancreatic cancer study.
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index and immediately bearish voices…
ThinkstockBoulder, Colo., ranked as the city least plagued by obesity, according to recent research. Among the 10 cities with the lowest level of obesity, another two also are in Colorado — Denver and Fort…
Amgen submitted an SEC Filing showing that, as of April 1, one of its subsidiaries and a GlaxoSmithKline subsidiary have terminated part and amended part of a collaboration agreement from 2009.
New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new research report, Jefferies presents the top drug innovations that investors should follow for 2014.